Blisibimod prospects look brighter as data mature

One month after shares of Anthera Pharmaceuticals Inc. took a 30 percent haircut following a phase III miss by blisibimod in SLE, investors did an about-face on maturing data from the phase BRIGHT-SC proof-of-concept study of the same agent.